GlassScriptPhysician profile
Eleazar Flores
NPI 1366885576
$13,615.12
in general payments reported to CMS, 2019-2025
52 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,446 · 2020: $1,650 · 2021: $2,866 · 2022: $2,724 · 2023: $2,153 · 2024: $1,557 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,930.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,108.94 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,721.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,397.38 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,231.93 | 2021 | |
| Lilly USA, LLC | $1,000.20 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $928.21 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $726.90 | 2019-2024 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $485.28 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $439.57 | 2022-2025 | |
| Glaxosmithkline, LLC. | $430.23 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Antares Pharma, INC. | $397.62 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Merck Sharp & Dohme LLC | $365.93 | 2019-2022 | |
| Pfizer INC. | $272.64 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $237.10 | 2020-2025 | |
| Allergan, INC. | $129.23 | 2020 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleazar Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.